A nonbiologic oral IL-23 inhibitor is more effective and safer than an approved oral JAK inhibitor for moderate-to-severe ...

Medicus Pharma (MDCX) announced feedback from Type C meeting with United States Food and Drug Administration. The purpose of the Type C meeting ...

(Reuters) -Merck's oral drug met the main goal of reducing bad cholesterol in a late-stage trial, it said on Tuesday, marking a second win for the drug since June. The trial data provides a shot in ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase 2 clinical trial. If approved, the drug, called MariTide, could make Amgen ...

In support of that hypothesis, Braca's team pointed to a previous study led by Sinclair and published in the journal Brain in 2023. It suggested that exenatide, another GLP-1 drug, lowers brain ...

Trial will evaluate DF-003, a first-in-class ALPK1 inhibitor that specifically targets the genetic root cause of ROSAH syndrome Drug Farm, a private biotechnology company utilizing genetics and ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. CHICAGO — Amgen’s monthly ...

Harmony Biosciences said on Wednesday its experimental drug for a rare genetic disorder failed to meet the main goal in a late-stage trial, sending its shares down more than 8%.

Viking Therapeutics' stock was crushed after a mid-stage trial of its oral weight-loss drug. Viking Therapeutics Inc. on Tuesday announced that a trial showed its oral weight-loss drug works - and ...